Terms: = Uterine cancer AND TFE3, RCCP2, 7030, ENSG00000068323, TFEA AND Prognosis
5 results:
1. [Endometrial and other rare uterine sarcomas : Diagnostic aspects in the context of the 2020 WHO classification].
Mayr D; Horn LC; Hiller GGR; Höhn AK; Schmoeckel E
Pathologe; 2022 May; 43(3):183-195. PubMed ID: 35362728
[TBL] [Abstract] [Full Text] [Related]
2. [Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma].
Yu YF; He SM; Wu YC; Xiong SW; Shen Q; Li YY; Yang F; He Q; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 53(4):640-646. PubMed ID: 34393221
[TBL] [Abstract] [Full Text] [Related]
3. Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer.
Engerud H; Hope K; Berg HF; Fasmer KE; Tangen IL; Haldorsen IS; Trovik J; Krakstad C
PLoS One; 2019; 14(1):e0210585. PubMed ID: 30645608
[TBL] [Abstract] [Full Text] [Related]
4. Alveolar soft part sarcoma of the uterine cervix in a woman presenting with postmenopausal bleeding: a case report and literature review.
Kang WD; Heo SH; Choi YD; Choi HS; Kim SM
Eur J Gynaecol Oncol; 2011; 32(3):359-61. PubMed ID: 21797137
[TBL] [Abstract] [Full Text] [Related]
5. A case of primary alveolar soft part sarcoma of the uterine cervix and a review of the literature.
Hasegawa K; Ichikawa R; Ishii R; Oe S; Kato R; Kobayashi Y; Kuroda M; Udagawa Y
Int J Clin Oncol; 2011 Dec; 16(6):751-8. PubMed ID: 21519815
[TBL] [Abstract] [Full Text] [Related]
